Boundless Bio, Inc. (BOLD) 10-Year Financial Performance & Capital Metrics

BOLD • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutBoundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.Show more

Revenue $0
EBITDA -$72M -34.1%
Net Income -$65M -32.2%
EPS (Diluted) -3.85 -73.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -554.86%
ROIC -475.88%
Debt/Equity 0.32
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 23.6% through buybacks
✓Trading at only 0.1x book value

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM-4.36%

ROCE

10Y Avg-45.62%

5Y Avg-41.77%

3Y Avg-51.9%

Latest-45.96%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	1.09M
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0	-1.09M
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-
Operating Expenses+	60.05M	93.18M	134.37M	25.3M	46.47M	54.8M	72.18M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	11.28M	17.27M	30M	6.02M	9.31M	12.16M	18M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	48.77M	75.9M	104.37M	19.28M	37.16M	42.64M	55.27M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	-1.09M
Operating Income+	-60.05M	-93.18M	-134.37M	-25.3M	-46.47M	-54.8M	-73.27M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.55%	-0.44%	0.81%	-0.84%	-0.18%	-0.34%
EBITDA+	-58.47M	-89.43M	-126.92M	-24.62M	-45.53M	-53.84M	-72.18M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.53%	-0.42%	0.81%	-0.85%	-0.18%	-0.34%
D&A (Non-Cash Add-back)	1.58M	3.75M	7.46M	682K	942K	957K	1.09M
EBIT	-60.05M	-93.18M	0	-25.3M	-46.47M	-54.8M	-65.36M
Net Interest Income+	0	0	0	96K	668K	5.28M	7.89M
Interest Income	0	0	0	96K	668K	5.28M	7.89M
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	378K	693K	5.55M	91K	568K	5.36M	7.9M
Pretax Income+	-59.67M	-92.48M	-128.82M	-25.21M	-45.9M	-49.43M	-65.36M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	378K	-2.25M	0	0	0	0	0
Effective Tax Rate %	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-59.67M	-90.24M	-128.82M	-25.21M	-45.9M	-49.43M	-65.36M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.51%	-0.43%	0.8%	-0.82%	-0.08%	-0.32%
Net Income (Continuing)	-59.67M	-90.24M	-128.82M	-25.21M	-45.9M	-49.43M	-65.36M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-5.59	-3.40	-2.93	-1.13	-2.06	-2.22	-3.85
EPS Growth %	-	0.39%	0.14%	0.61%	-0.82%	-0.08%	-0.73%
EPS (Basic)	-1.36	-2.05	-2.93	-1.13	-2.06	-2.22	-3.85
Diluted Shares Outstanding	10.67M	26.58M	44.03M	22.24M	22.24M	22.24M	16.98M
Basic Shares Outstanding	44.03M	44.03M	44.03M	22.24M	22.24M	22.24M	16.98M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	108.44M	137.01M	419.77M	74.57M	68.04M	124.2M	154.39M
Cash & Short-Term Investments	104.88M	133.6M	414.31M	73.03M	66.72M	120.75M	152.11M
Cash Only	36.36M	38.97M	144.35M	34.29M	10.95M	23.71M	26.59M
Short-Term Investments	68.52M	94.64M	269.96M	38.74M	55.77M	97.05M	125.53M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	3.55M	3.4M	5.46M	1.54M	1.32M	3.45M	2.28M
Total Non-Current Assets+	33.62M	41.65M	52.78M	39.15M	8.79M	5.69M	52.02M
Property, Plant & Equipment	18.94M	24.37M	32.1M	3.1M	7.73M	4.58M	51.36M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	3.63M	3.63M	3.63M	0	0	0	0
Intangible Assets	8M	8M	8M	0	0	0	0
Long-Term Investments	0	0	0	34.99M	0	560K	0
Other Non-Current Assets	1.84M	3.09M	6.43M	1.07M	1.07M	555K	659K
Total Assets+	142.06M	178.66M	472.56M	113.72M	76.83M	129.89M	206.41M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	0.26%	1.64%	-0.76%	-0.32%	0.69%	0.59%
Total Current Liabilities+	12.56M	17.71M	23.85M	3.87M	7.73M	9.36M	8.13M
Accounts Payable	2.42M	3.85M	8.12M	1.07M	1.4M	2.22M	1.27M
Days Payables Outstanding	-	-	-	-	-	-	428.19
Short-Term Debt	265K	4.64M	2.35M	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0
Other Current Liabilities	6.9M	3.65M	5.67M	1.51M	2.55M	2.9M	2.78M
Current Ratio	8.63x	7.74x	17.60x	19.28x	8.80x	13.27x	18.98x
Quick Ratio	8.63x	7.74x	17.60x	19.28x	8.80x	13.27x	18.98x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.52M	6.08M	10.45M	148.04M	150.8M	247.62M	47.63M
Long-Term Debt	2.49M	2.54M	4.72M	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.85M	0	47.63M
Deferred Tax Liabilities	3.26M	1.01M	1.01M	0	0	0	0
Other Non-Current Liabilities	0	0	0	148.04M	147.95M	247.62M	0
Total Liabilities	22.69M	22.06M	29.8M	151.91M	158.53M	256.98M	55.77M
Total Debt+	2.75M	7.18M	7.07M	377K	5.18M	2.19M	47.63M
Net Debt	-33.61M	-31.79M	-137.28M	-33.91M	-5.77M	-21.51M	21.05M
Debt / Equity	0.02x	0.05x	0.02x	-	-	-	0.32x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	119.37M	156.6M	442.75M	-38.19M	-81.7M	-127.08M	150.64M
Equity Growth %	-	0.31%	1.83%	-1.09%	-1.14%	-0.56%	2.19%
Book Value per Share	11.18	5.89	10.06	-1.72	-3.67	-5.71	8.87
Total Shareholders' Equity	119.37M	156.6M	442.75M	-38.19M	-81.7M	-127.08M	150.64M
Common Stock	300M	300M	300M	2K	0	0	2K
Retained Earnings	-100.41M	-190.65M	-319.47M	-40.77M	-86.67M	-136.11M	-201.47M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-29K	-80K	-60K	-175K	-398K	40K	121K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-49.02M	-84.51M	-107.98M	-23.25M	-39.6M	-46.85M	-60.84M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.72%	-0.28%	0.78%	-0.7%	-0.18%	-0.3%
Net Income	-59.67M	-90.24M	-128.82M	-25.21M	-45.9M	-49.43M	-65.36M
Depreciation & Amortization	1.58M	3.75M	7.46M	682K	942K	957K	1.09M
Stock-Based Compensation	2M	6.88M	0	1.16M	0	3.34M	7.52M
Deferred Taxes	-95.21M	2.25M	0	0	0	0	0
Other Non-Cash Items	7.07M	-30.57M	-279.73M	959K	4.5M	-915K	-2.4M
Working Capital Changes	95.21M	23.42M	276.62M	-837K	866K	-799K	-1.68M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	-671K	686K	4.08M	0	1.91M	0	775K
Cash from Investing+	-62.05M	-33.44M	-185.05M	-59.28M	16.13M	-38.26M	-26.1M
Capital Expenditures	-16.65M	-7.55M	-11.61M	-2.03M	-1.07M	-633K	-2.54M
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	16K	0	0	0	0	0	0
Cash from Financing+	75.36M	120.55M	398.46M	105.53M	126K	97.9M	89.82M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	75.36M	120.55M	398.46M	208K	0	-1.77M	-3.18M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-65.67M	-92.06M	-119.59M	-25.28M	-40.66M	-47.49M	-63.38M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.4%	-0.3%	0.79%	-0.61%	-0.17%	-0.33%
FCF per Share	-6.15	-3.46	-2.72	-1.14	-1.83	-2.14	-3.73
FCF Conversion (FCF/Net Income)	0.82x	0.94x	0.84x	0.92x	0.86x	0.95x	0.93x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2021	2022	2023	2024
Return on Equity (ROE)	-49.99%	-65.4%	-42.99%	-12.46%	-	-	-554.86%
Return on Invested Capital (ROIC)	-52.51%	-66.37%	-46.84%	-16.26%	-	-	-475.88%
Debt / Equity	0.02x	0.05x	0.02x	-	-	-	0.32x
FCF Conversion	0.82x	0.94x	0.84x	0.92x	0.86x	0.95x	0.93x

Frequently Asked Questions

Growth & Financials

Boundless Bio, Inc. (BOLD) grew revenue by 0.0% over the past year. Growth has been modest.

Boundless Bio, Inc. (BOLD) reported a net loss of $61.8M for fiscal year 2024.

Dividend & Returns

Boundless Bio, Inc. (BOLD) has a return on equity (ROE) of -554.9%. Negative ROE indicates the company is unprofitable.

Boundless Bio, Inc. (BOLD) had negative free cash flow of $52.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener